This week, there are 16 drugs in the patent and exclusivity list. They are: - PF PRISM CV's INLYTA, containing active ingredient AXITINIB - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - IPSEN BIOPHARMACEUTICALS INC's ONIVYDE, containing active ingredient IRINOTECAN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM's GLYXAMBI, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRIJARDY XR, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRADJENTA, containing active ingredient LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO XR, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Read More

This week, there are 6 drugs in the patent and exclusivity list. They are: - ALEXZA PHARMACEUTICALS INC's ADASUVE, containing active ingredient LOXAPINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - CORMEDIX INC's DEFENCATH, containing active ingredient HEPARIN SODIUM; TAUROLIDINE - ABBVIE INC's VUITY, containing active ingredient PILOCARPINE HYDROCHLORIDE - SANOFI AVENTIS US LLC's AUBAGIO, containing active ingredient TERIFLUNOMIDE - ASTRAZENECA UK LTD's CALQUENCE, containing active ingredient ACALABRUTINIB Read More